Product
LNP023
Aliases
iptacopan
9 clinical trials
5 indications
Indication
GlomerulonephritisIndication
Paroxysmal Nocturnal HemoglobinuriaIndication
C3 GlomerulopathyIndication
IgA NephropathyIndication
Membranous nephropathyClinical trial
A Multi-center, Randomized, Open-label, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria and Active HemolysisStatus: Completed, Estimated PCD: 2020-04-07
Clinical trial
An Open-label, Non-randomized Study on Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LNP023 in Two Patient Populations With C3 GlomerulopathyStatus: Completed, Estimated PCD: 2021-04-23
Clinical trial
An Open-label, Non-randomized Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of LNP023 in Subjects With C3 GlomerulopathyStatus: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Randomized, Multicenter, Active-comparator Controlled, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult Patients With PNH and Residual Anemia, Despite Treatment With an Intravenous Anti-C5 Antibody.Status: Completed, Estimated PCD: 2022-09-26
Clinical trial
A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan in Adult Participants With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301Status: Recruiting, Estimated PCD: 2032-05-31
Clinical trial
A Randomized, Open-label, Two Arm, Parallel Group, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous NephropathyStatus: Terminated, Estimated PCD: 2023-01-20
Clinical trial
An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsStatus: Completed, Estimated PCD: 2020-12-29
Clinical trial
An Open-label Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316, an Anti-C5 Monoclonal Antibody in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Completed, Estimated PCD: 2022-05-24
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsStatus: Active (not recruiting), Estimated PCD: 2025-10-15